Nykode Therapeutics

VACC

NO0010714785

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-16 am EDT			5-day change	1st Jan Change
14.67 ^NOK	-0.41%		+4.41%	-31.45%

May. 14	Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024
May. 14	Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Vaccibody AS has Changed its Name to Nykode Therapeutics

November 23, 2021 at 01:00 am EST

Vaccibody AS changed its name to Nykode Therapeutics.

Latest news about Nykode Therapeutics

Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024	May. 14
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	May. 14	CI
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	Apr. 19	MT
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	Apr. 19	CI
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	Mar. 21	CI
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	Mar. 19	CI
Transcript : Nykode Therapeutics AS, Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Transcript : Nykode Therapeutics AS Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	Dec. 14	CI
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Transcript : Nykode Therapeutics AS, Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding	23-10-24	CI
Nykode Therapeutics AS announced that it expects to receive NOK 329.999987 million in funding	23-10-23	CI
Nykode Therapeutics Kicks off Early-stage Trial of Head, Neck Skin Cancer Treatment	23-09-29	MT
Nykode Therapeutics ASA Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer	23-09-28	CI
Transcript : Nykode Therapeutics AS - Analyst/Investor Day	23-09-20
Nykode Therapeutics ASA Announces Advances in Clinical Pipeline and Research	23-09-20	CI
Nykode Therapeutics Wins US FDA Nod for Mid-stage Study of Cervical Cancer Combo	23-09-05	MT
Nykode Therapeutics ASA Announces FDA Approval of IND for VB-C-04, a Trial of VB-C-04 in HPV16-Positive Cervical Cancer	23-09-04	CI
Transcript : Nykode Therapeutics AS, Q2 2023 Earnings Call, Aug 23, 2023	23-08-23
Nykode Therapeutics AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Nykode Adds New Cancer Vaccine Candidate in Clinical Trial Tie-up With Roche	23-06-01	MT

Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.

Sector

Biotechnology & Medical Research

Calendar

2024-08-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Nykode Therapeutics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.67 NOK

Average target price

43 NOK

Spread / Average Target

+193.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NYKODE THERAPEUTICS	-31.45%	449M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs

Nykode Therapeutics

Equities

VACC

NO0010714785

Biotechnology & Medical Research

Vaccibody AS has Changed its Name to Nykode Therapeutics

Latest news about Nykode Therapeutics

Chart Nykode Therapeutics

Company Profile

Income Statement Evolution

Ratings for Nykode Therapeutics

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs